<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824264</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066A2202</org_study_id>
    <secondary_id>2012-005793-63</secondary_id>
    <nct_id>NCT01824264</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Evaluate Change in HbA1c After 12 Weeks Monotherapy With 7 Doses of LIK066 Compared With Placebo or Sitagliptin in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of
      LIK066 to support dose selection for phase 3.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change from baseline in HbA1c after 12 weeks of treatment in each of the LIK066 doses and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting Plasma Glucose</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on fasting plasma glucose after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinary glucose to creatinine ratio</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on urinary glucose to creatinine ratio after 12 weeks of treatment will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in body weight after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Blood pressure</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in systolic and diastolic blood pressure after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial glucose during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in postprandial glucose during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in beta cell function during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in beta cell function during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin secretion relative to glucose during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066on change in insulin secretion relative to glucose during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oral glucose insulin sensitivity during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in oral glucose insulin sensitivity during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucagon-like peptide response during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in glucagon-like peptide during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Peptide YY response during a meal test</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on change in peptide YY response during a meal test after 12 weeks of treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events to assess safety and tolerability of LIK066</measure>
    <time_frame>12 weeks</time_frame>
    <description>The safety and tolerability of 7 doses of LIK066 after 12 weeks of treatment will be evaluated with number of patients reported for total adverse events, serious adverse events and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in renal threshold for glucose excretion</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The effect of LIK066 on renal threshold for glucose excretion will be calculated from glucose values in an overnight urine collection</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LIK066 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2.5 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 5 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 10 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 25 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 50 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 100 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 150 mg of LIK066 once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 100 mg sitagliptin once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>Experimental treatment doses</description>
    <arm_group_label>LIK066 2.5 mg</arm_group_label>
    <arm_group_label>LIK066 5 mg</arm_group_label>
    <arm_group_label>LIK066 10 mg</arm_group_label>
    <arm_group_label>LIK066 25 mg</arm_group_label>
    <arm_group_label>LIK066 50 mg</arm_group_label>
    <arm_group_label>LIK066 100 mg</arm_group_label>
    <arm_group_label>LIK066 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Active comparator treatment dose</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of T2DM by standard criteria

          2. Drug-naïve patients, defined as patients not having received any anti-diabetic
             medication previously,

          3. Currently untreated patients , who, after the diagnosis of T2DM, have received
             anti-diabetic medication for not more than 12 consecutive weeks, and have not received
             any anti-diabetic treatment within 12 weeks prior to Visit 1

          4. Patients being treated with mono-therapy for at least 8 consecutive weeks prior to
             Visit 1 with the following OADs: metformin, dipeptidyl peptidase-4 inhibitors
             (DPP-4i), SU, glinide, alpha-glucosidase inhibitor (AGI)

          5. HbA1c ≥ 7 to ≤ 10.5% at Visit 1 for drug-naïve/currently untreated patients

          6. HbA1c ≥ 7 to ≤ 9.5% at Visit 1 for patients treated with OAD monotherapy

          7. HbA1c ≥ 7 to ≤ 10.5% at Visit 199 for ALL patients

          8. Age: ≥18 and ≤ 75 years old at Visit 1

          9. BMI ≥22 to ≤45 kg/m2 at Visit 1

        Exclusion Criteria:

          1. FPG ≥270 mg/dl (15 mmol/L) for drug-naïve/currently untreated patients or ≥240 mg/dl
             (13.3 mmol/L) for patients on OAD monotherapy at Visit 1

          2. Insulin treatment &gt;4 consecutive weeks in the last 6 months, corticosteroid use &gt;7
             days in the last 8 weeks, use of growth hormones in the last 6 months, or use of
             weight control products &gt; 4 weeks in the last 6 months

          3. History of acute metabolic complications, CV disease, type 1 diabetes mellitus,
             hepatic disorders, pancreatitis, chronic diarrhea

          4. Significant lab abnormalities such as TSH outside of normal range, UACR&gt;300 mg/g
             creatinine, eGFR &lt;60 ml/min/1.73m2, hemoglobin &lt;12 g/L in men and &lt;11 g/L in women,
             hematuria

          5. ECG abnormalities including AV block, long QT syndrome or QTc&gt;450 msec for men and
             &gt;470 msec for women

          6. History of malignancy

          7. Women of child-bearing potential not using effective methods of contraception Other
             protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Hungary</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes mellitus, SGLT inhibitors, dose-response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

